A Phase IIb Study Testing The Combination Of Methotrexate And CF101 In Rheumatoid Arthritis Patients Failed To Achieve Primary Efficacy Endpoint

Podiatry Arena A Phase IIb Study Testing The Combination Of Methotrexate And CF101 In Rheumatoid Arthritis Patients Failed To Achieve Primary Efficacy Endpoint

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

A Phase IIb Study Testing The Combination Of Methotrexate And CF101 In Rheumatoid Arthritis Patients Failed To Achieve Primary Efficacy Endpoint

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

8th May 2009, 07:30 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 3,062

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 5 Times in 5 Posts

A Phase IIb Study Testing The Combination Of Methotrexate And CF101 In Rheumatoid Arthritis Patients Failed To Achieve Primary Efficacy Endpoint

Podiatry Arena members do not see these ads

Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, announced that top line results from its Phase IIb study in rheumatoid arthritis (RA) patients indicate that the study failed to achieve its primary efficacy endpoint. The Phase IIb RA study enrolled 230 patients in 21 sites in Europe and in Israel. The patients were randomized into 3 groups treated, twice daily, orally, with 0.1 mg or 1 mg of CF101, or placebo.

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis	RSSFeedBot	Latest Rheumatology News	0	27th December 2008 04:21 AM
Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (RA)	RSSFeedBot	Latest Rheumatology News	0	26th December 2008 05:30 AM
Non- Steroidal Combination Drug To Treat Psoriasis - Positive Phase 2b Results Showing Efficacy And Synergy DPS-101	RSSFeedBot	Latest Dermatology News	0	4th November 2008 01:21 PM
More Patients With Early Erosive Rheumatoid Arthritis Treated With ORENCIA(R) And Methotrexate Achieved DAS28 (CRP)-Defined Remission Versus MTX Alone	RSSFeedBot	Latest Rheumatology News	0	28th October 2008 08:40 AM
ACTEMRA (R) (tocilizumab) Significantly Reduced Signs And Symptoms Of Rheumatoid Arthritis In Patients Who Failed Prior Treatments	RSSFeedBot	Latest Rheumatology News	0	28th October 2008 03:21 AM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 05:33 AM.

User Name		Remember Me?
Password